Loading...
Market
Top Sales Region for PTC518 in First Two Years?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Sales reports from PTC Therapeutics and Novartis
Story
PTC Therapeutics Secures $2.9B Deal with Novartis for Huntington's Drug, $1B Upfront
Dec 2, 2024, 01:09 PM
PTC Therapeutics Inc. has entered into a significant licensing agreement with Novartis AG, focusing on the development of PTC518, an experimental drug for Huntington's disease. The deal, which could be worth up to $2.9 billion, includes an upfront payment of $1 billion to PTC Therapeutics. Under the terms, Novartis will share U.S. profits and losses with PTC Therapeutics on a 40/60 basis, with PTC receiving 40%. This collaboration marks Novartis's renewed interest in Huntington's disease treatments. The agreement also involves global licensing and collaboration for the drug's development, with Novartis taking the lead in further development efforts.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
United States only • 25%
United States and European Union • 25%
United States, European Union, and Japan • 25%
Other combinations or none • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Africa • 25%
Asia • 25%
Latin America • 25%
Other • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%